Castle Biosciences (CSTL) Corporate presentation summary

Mission and vision

• Aims to improve health through innovative tests that guide patient care decisions.

• Seeks to transform disease management by prioritizing patients, clinicians, employees, and investors.

Strategic focus and clinical impact

• Focuses on diagnostic support, risk stratification, and therapy selection across dermatology, ophthalmology, and gastroenterology.

• Builds robust clinical evidence for best-in-class tests addressing high unmet needs and significant market opportunities.

• Demonstrated that DecisionDx-Melanoma reduces unnecessary sentinel lymph node biopsies and improves patient outcomes.

• DecisionDx-SCC improves risk stratification and guides adjuvant radiation therapy, potentially saving Medicare up to $972 million annually.

• TissueCypher outperforms clinicopathologic factors in identifying high-risk Barrett's esophagus patients.

Product performance and clinical validation

• DecisionDx-Melanoma provides precise, personalized risk prediction and is associated with improved survival and earlier recurrence detection.

• Outperforms AJCC8 staging in risk stratification for stage I melanoma.

• DecisionDx-SCC predicts metastatic risk and ART benefit, with Class 2B patients showing significant benefit from ART.

• TissueCypher recognized in AGA guidelines for identifying patients at increased risk of esophageal cancer.